Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Vifor Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In pregnancy Restless Legs Syndrome(RLS) is more common than in the general population. During pregnancy iron tablets are the only available safe medication but their efficacy is rather poor. It is the aim of this study to examine the efficacy, practicability and safety of the drug Ferinject® containing the active agent Ferric carboxymaltose for the therapy of Restless Legs Syndrome(RLS) during pregnancy in the case of iron deficiency or anaemia.
20 women with RLS and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses. Repeated blood tests, pre-and post-therapy actigraphy as well as repeated answering of questionnaires concerning Restless Legs Syndrome(RLS)-symptoms and sleep quality will show the effect of iv-Iron supplementation on Restless Legs Syndrome(RLS)-symptoms during pregnancy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ferric carboxymaltose | Experimental | Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ferric carboxymaltose | Drug | 20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses. |
| Measure | Description | Time Frame |
|---|---|---|
| Primary endpoint: = 50% reduction of RLS symptoms as measured by International Restless Legs Study Group (IRLSS) | 3 days, 7 days, 14 days, 28 days, and 60 days after iron infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of Periodic Limb Movements in Sleep (PLMS) ≥50% as measured with actimetry | screening, 7 days, 14 days after iron infusion | |
| Improvement of sleep according to the Pittsburgh Sleep Quality Questionnaire (PSQI) | screening, 7 days after iron infusion, 14 days post partum |
Not provided
Inclusion criteria:
Pregnant women, singleton pregnancy, in the 3rd trimester
Iron Deficiency (Anaemia) defined as Serum Ferritin < 35ug/l with or without Hb < 11g/dl.
Fulfilling the 4 criteria of the International Restless Legs Study Group (IRLSS)
RLS score > 20 (defined as modest to severe RLS symptoms) or RLS symptoms = 3 times per week
Patients = 18 years
Signed informed consent provided
Exclusion criteria: Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Claudio Bassetti, Professor | University Hospital Zurich, Neurology | Principal Investigator |
| Claudio Bassetti, Professor | Neuroenter of Southern Switzerland, Ospedale Civico, Lugano | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Zurich, Neurology | Zurich | Canton of Zurich | 8091 | Switzerland | ||
| Neurocenter of Southern Switzerland, Ospedale Civico |
Not provided
| ID | Term |
|---|---|
| D012148 | Restless Legs Syndrome |
| D018798 | Anemia, Iron-Deficiency |
| D000090463 | Iron Deficiencies |
| D000740 | Anemia |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C522335 | ferric carboxymaltose |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Improvement of sleepiness using Epworth Sleepiness Scale (ESS) | screening, 7 days, 14 days, 28 days after iron infusion, 14 days post partum |
| Improvement of fatigue using Fatigue Severity Scale (FSS) | screening, 7 days, 14 days, 28 days after iron infusion, 14 days post partum |
| Safety of ferric carboxymaltose during pregnancy in the 3rd trimester | Recording of adverse events | Day 1, Day 3, Day 7, Day 14, Day 28, 14 days pre partum, 14 days post partum |
| Parameters of the newborn baby (apgar, umbilical artery pH, weight, mode of delivery) | 8 weeeks |
| Lugano |
| Canton Ticino |
| 6903 |
| Switzerland |
| D020447 |
| Parasomnias |
| D001523 | Mental Disorders |
| D000747 | Anemia, Hypochromic |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D019189 | Iron Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |